Henry Schein Inc. News
Signs of Hope: Cramer's 'Mad Money' Recap (Monday 3/30/20)
Jim Cramer says all hopes for the stock market the economy hang in the balance, and the U.S. needs to do more to fight COVID-19.
Coronavirus Latest Updates: A Timeline of Recent Events
Here is TheStreet's latest news on the coronavirus and its worldwide and economic impact, and a timeline of events since January
Henry Schein Says Rapid Test for Coronavirus Available
Henry Schein says it can provide a coronavirus blood test that can deliver results within 15 minutes.
Dow Futures, Uber, Shake Shack and China Trade - 5 Things You Must Know Tuesday
U.S. stock futures rise a day after the three major U.S. benchmark indexes posted record closing highs on positive trade developments between the U.S. and China and strong corporate earnings; Uber posts $1.2 billion loss but sees profitability in 2021; Shake Shacks sinks on a weak same-store sales forecast.
Dow Futures, SAP, Brexit, Boeing, Opioid Trial - 5 Things You Must Know
U.S. stock futures rise modestly Monday amid hopes for progress in the trade war between the U.S. and China but also uncertainties about Britain's exit from the European Union.
Netflix, Bank of America, Opioid Settlement, Brexit, MGM- 5 Things You Must Know
U.S. stock futures decline as Wall Street awaits another round of third-quarter earnings reports and global stocks trade mixed as investors monitored Brexit developments; Netflix, IBM and Bank of America report earnings Wednesday; McKesson, AmerisourceBergen and Cardinal Health reportedly are in talks to pay $18 billion to settle thousands of opioid-related lawsuits.
Don't Forget the Consumer: Cramer's 'Mad Money' Recap
Jim Cramer says we have a $19 trillion economy, and two-thirds of it is based on consumer spending -- not manufacturing, or sales, or industry.
Trump's Potential Return to Twitter Under Musk Hits Digital World
Digital World Acquisition, a company attempting to merge with former President Donald Trump's media group Truth Social, faces a new challenge.
Bluebird Bio's 2nd Approval Doesn't Guarantee Survival
Investors hoping for a revival at the struggling biotech might want to temper their expectations.